[go: up one dir, main page]

MA56674B1 - Composés macrocycliques utilisés en tant qu'agonistes sting et procédés et utilisations de ceux-ci - Google Patents

Composés macrocycliques utilisés en tant qu'agonistes sting et procédés et utilisations de ceux-ci

Info

Publication number
MA56674B1
MA56674B1 MA56674A MA56674A MA56674B1 MA 56674 B1 MA56674 B1 MA 56674B1 MA 56674 A MA56674 A MA 56674A MA 56674 A MA56674 A MA 56674A MA 56674 B1 MA56674 B1 MA 56674B1
Authority
MA
Morocco
Prior art keywords
methods
macrocyclic compounds
sting agonists
compounds
macrocyclic
Prior art date
Application number
MA56674A
Other languages
English (en)
Inventor
Vidya Ramdas
Moloy BANERJEE
Rajender Kumar Kamboj
Vinod Popatrao Vyavahare
Venkata P. Palle
Navnath Popat Karche
Nishant Ramnivasji GUPTA
Ganesh Rajaram Jadhav
Amit Kumar Das
Deepak Sahebrao Walke
Vaibhav Madhukar Kalhapure
Smita Aditya BHOSKAR
Original Assignee
Lupin Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=72422197&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA56674(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lupin Limited filed Critical Lupin Limited
Publication of MA56674B1 publication Critical patent/MA56674B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des composés macrocycliques de Formule générale (I) ou (II) et leurs formes tautomères, des stéréoisomères, des sels pharmaceutiquement acceptables, des hydrates, des solvates et des promédicaments de ceux-ci, et leur combinaison avec un médicament approprié, des procédés correspondants pour la synthèse et des compositions pharmaceutiques et des utilisations des composés décrits dans l'invention.
MA56674A 2019-07-22 2020-07-22 Composés macrocycliques utilisés en tant qu'agonistes sting et procédés et utilisations de ceux-ci MA56674B1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN201921029556 2019-07-22
IN201921051086 2019-12-10
IN202021003961 2020-01-29
PCT/IB2020/056875 WO2021014365A1 (fr) 2019-07-22 2020-07-22 Composés macrocycliques utilisés en tant qu'agonistes sting et procédés et utilisations de ceux-ci
EP20768090.1A EP4004002B1 (fr) 2019-07-22 2020-07-22 Composés macrocycliques utilisés en tant qu'agonistes sting et procédés et utilisations de ceux-ci

Publications (1)

Publication Number Publication Date
MA56674B1 true MA56674B1 (fr) 2024-09-30

Family

ID=72422197

Family Applications (1)

Application Number Title Priority Date Filing Date
MA56674A MA56674B1 (fr) 2019-07-22 2020-07-22 Composés macrocycliques utilisés en tant qu'agonistes sting et procédés et utilisations de ceux-ci

Country Status (33)

Country Link
US (1) US12479858B2 (fr)
EP (1) EP4004002B1 (fr)
JP (1) JP7592689B2 (fr)
KR (1) KR20220035955A (fr)
CN (1) CN114174303B (fr)
AU (1) AU2020319058B2 (fr)
BR (1) BR112022001125A2 (fr)
CA (1) CA3147397A1 (fr)
CL (1) CL2022000145A1 (fr)
CO (1) CO2022001814A2 (fr)
CR (1) CR20220029A (fr)
DK (1) DK4004002T3 (fr)
EC (1) ECSP22005485A (fr)
ES (1) ES2989915T3 (fr)
FI (1) FI4004002T3 (fr)
GE (2) GEP20247627B (fr)
HR (1) HRP20241222T1 (fr)
HU (1) HUE068456T2 (fr)
IL (1) IL289740B2 (fr)
LT (1) LT4004002T (fr)
MA (1) MA56674B1 (fr)
MX (1) MX420195B (fr)
PE (1) PE20220937A1 (fr)
PH (1) PH12022550175A1 (fr)
PL (1) PL4004002T3 (fr)
PT (1) PT4004002T (fr)
RS (1) RS66126B1 (fr)
SA (1) SA522431429B1 (fr)
SI (1) SI4004002T1 (fr)
SM (1) SMT202400399T1 (fr)
UA (1) UA129653C2 (fr)
WO (1) WO2021014365A1 (fr)
ZA (1) ZA202201375B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019011655A (es) 2017-03-29 2019-12-19 Legochem Biosciences Inc Profarmaco de dimero de pirrolobenzodiazepina y compuesto conjugado ligando-conector de este.
BR112021026267A2 (pt) 2019-07-22 2022-05-31 Boehringer Ingelheim Int Derivados de n-metil, n-((6-(metoxi)piridazin-3-il)amina como moduladores de autotaxina (atx) para o tratamento de doenças fibróticas ou inflamatórias das vias aéreas
JP2022543086A (ja) 2019-08-02 2022-10-07 メルサナ セラピューティクス インコーポレイテッド がんの処置用のＳＴＩＮＧ（インターフェロン遺伝子刺激因子）アゴニストとしてのビス－［Ｎ－（（５－カルバモイル）－１Ｈ－ベンゾ［ｄ］イミダゾール－２－イル）－ピラゾール－５－カルボキサミド］誘導体および関連化合物
CA3174297A1 (fr) 2020-04-02 2021-10-07 Jeremy R. Duvall Conjugues anticorps-medicament comprenant des agonistes de sting
JPWO2021206158A1 (fr) 2020-04-10 2021-10-14
JP2024503508A (ja) * 2021-01-15 2024-01-25 シージェン インコーポレイテッド 免疫調節性抗体－薬物コンジュゲート
AR125608A1 (es) * 2021-03-30 2023-08-02 Jacobio Pharmaceuticals Co Ltd Novedosos compuestos útiles como agonistas de sting y sus usos
EP4638460A1 (fr) * 2022-12-22 2025-10-29 Aculeus Therapeutics Pty Ltd Dérivés de benzimidazole pour la modulation du sting
AR133167A1 (es) * 2023-07-07 2025-09-03 Hoffmann La Roche Macrociclos para el tratamiento de enfermedad autoinmunitaria
AR133266A1 (es) * 2023-07-19 2025-09-10 Hoffmann La Roche Macrociclos para el tratamiento de enfermedades autoinmunitarias
CN119490423A (zh) * 2023-08-15 2025-02-21 沈阳中化农药化工研发有限公司 一种制备2-氟-3-氨基苯甲酸及其酯类化合物的方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20010395A1 (it) 2001-02-27 2002-08-27 Dompe Spa Omega-amminoalchilammidi di acidi r-2-aril-propionici come inibitori della chemiotassi di cellule polimorfonucleate e mononucleate
AR046959A1 (es) 2003-12-18 2006-01-04 Tibotec Pharm Ltd Morfolinilo que contiene bencimidazoles como inhibidores de la replicacion del virus sincitial respiratorio
US7488736B2 (en) 2004-05-17 2009-02-10 Epix Delaware, Inc. Thienopyridinone compounds and methods of treatment
NZ567140A (en) 2005-10-07 2011-09-30 Exelixis Inc Azetidines as MEK inhibitors for the treatment of proliferative diseases
WO2007146981A2 (fr) 2006-06-15 2007-12-21 Boehringer Ingelheim International Gmbh 2-anilino-4-(hétérocyclique)amino-pyrimidines
WO2008090570A1 (fr) 2007-01-25 2008-07-31 Panacea Biotec Ltd Nouveaux antimicrobiens
TW201000447A (en) 2008-05-30 2010-01-01 Astrazeneca Ab New compounds useful in pain therapy
WO2011091446A1 (fr) * 2010-01-22 2011-07-28 Glaxosmithkline Llc Composés chimiques
EP2651926A4 (fr) * 2010-12-15 2014-07-09 Abbvie Inc Composés anti-viraux
MX2015007862A (es) 2012-12-28 2016-02-05 Nippon Zoki Pharmaceutical Co Derivado de amida del acido cinamico.
EP3152217B1 (fr) * 2014-06-04 2018-08-01 GlaxoSmithKline Intellectual Property Development Limited Di-nucléotides cycliques utilisés comme modulateurs de sting
US20180147187A1 (en) 2015-01-12 2018-05-31 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
EP3325473A4 (fr) 2015-07-22 2019-06-26 The Royal Institution for the Advancement of Learning / McGill University Composés et leurs utilisations dans le traitement de cancers et d'autres états médicaux
AU2017247798C1 (en) * 2016-04-07 2020-08-27 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators
US10975287B2 (en) 2016-04-07 2021-04-13 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators
KR20190038485A (ko) 2016-05-27 2019-04-08 항저우 인노게이트 파마 컴퍼니 리미티드 Fgfr4 저해제인 헤테로 고리 화합물
EA036338B1 (ru) * 2017-02-22 2020-10-28 Глэксосмитклайн Интеллекчуал Проперти Девелопмент Лимитед Гетероциклические амиды, пригодные в качестве модуляторов белков
US20200138827A1 (en) 2017-06-22 2020-05-07 Curadev Pharma Limited Small molecule modulators of human sting
WO2018234807A1 (fr) 2017-06-22 2018-12-27 Curadev Pharma Limited Modulateurs hétérocycliques à petites molécules de sting humain
PE20200696A1 (es) 2017-06-22 2020-06-16 Curadev Pharma Ltd Moduladores de moleculas pequenas de sting humana
JP7274478B2 (ja) 2017-07-27 2023-05-16 スティングレイ・セラピューティクス・インコーポレイテッド 置換された－３Ｈ－イミダゾ［４，５－ｃ］ピリジン及び１Ｈ－ピロロ［２，３－ｃ］ピリジンシリーズの新規なエクトヌクレオチドピロホスファターゼ／ホスホジエステラーゼ－１（ＥＮＰＰ１）並びにがん免疫治療薬としてのインターフェロン遺伝子（ＳＴＩＮＧ）モジュレータのための刺激剤
EP3661498A4 (fr) 2017-08-04 2021-04-21 Merck Sharp & Dohme Corp. Agonistes benzo[b]thiophène de sting pour le traitement du cancer
WO2019027857A1 (fr) 2017-08-04 2019-02-07 Merck Sharp & Dohme Corp. Combinaisons d'antagonistes de pd-1 et d'agonistes de sting benzo[b]thiophéniques pour le traitement du cancer
US11377440B2 (en) 2017-10-05 2022-07-05 Glaxosmithkline Intellectual Property Development Limited Modulators of stimulator of interferon genes (STING)
US20210238172A1 (en) 2017-10-05 2021-08-05 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators and methods of using the same
WO2020132582A1 (fr) * 2018-12-21 2020-06-25 Nimbus Titan, Inc. Agonistes de sting et leurs utilisations
AU2020245263B2 (en) * 2019-03-28 2025-07-03 Lupin Limited Macrocyclic compounds as sting agonists

Also Published As

Publication number Publication date
MX420195B (es) 2025-02-10
JP2022541330A (ja) 2022-09-22
PH12022550175A1 (en) 2022-11-14
IL289740B1 (en) 2025-06-01
UA129653C2 (uk) 2025-06-25
EP4004002A1 (fr) 2022-06-01
PE20220937A1 (es) 2022-05-31
MX2022000939A (es) 2022-04-06
IL289740B2 (en) 2025-10-01
HUE068456T2 (hu) 2024-12-28
ZA202201375B (en) 2022-09-28
IL289740A (en) 2022-03-01
PT4004002T (pt) 2024-10-07
CA3147397A1 (fr) 2021-01-28
CR20220029A (es) 2022-03-14
CO2022001814A2 (es) 2022-04-29
SI4004002T1 (sl) 2024-12-31
HRP20241222T1 (hr) 2024-12-06
AU2020319058A1 (en) 2022-02-17
ES2989915T3 (es) 2024-11-28
RS66126B1 (sr) 2024-11-29
FI4004002T3 (fi) 2024-10-04
BR112022001125A2 (pt) 2022-03-15
US20220289763A1 (en) 2022-09-15
ECSP22005485A (es) 2022-02-25
JP7592689B2 (ja) 2024-12-02
CN114174303A (zh) 2022-03-11
AU2020319058B2 (en) 2025-10-02
SMT202400399T1 (it) 2024-11-15
KR20220035955A (ko) 2022-03-22
GEP20247627B (en) 2024-05-27
LT4004002T (lt) 2024-10-25
GEAP202415883A (en) 2024-02-12
SA522431429B1 (ar) 2024-11-11
PL4004002T3 (pl) 2024-11-18
CN114174303B (zh) 2024-06-25
DK4004002T3 (da) 2024-09-30
CL2022000145A1 (es) 2022-09-09
WO2021014365A1 (fr) 2021-01-28
US12479858B2 (en) 2025-11-25
EP4004002B1 (fr) 2024-07-10

Similar Documents

Publication Publication Date Title
MA56674B1 (fr) Composés macrocycliques utilisés en tant qu'agonistes sting et procédés et utilisations de ceux-ci
MA29685B1 (fr) Composes spiroheterocycliques et leurs utilisations en tant qu'agents therapeutiques
MA58004B1 (fr) Dérivés de pyrazolyle utiles en tant qu'agents anticancéreux
MA46101A (fr) Modulateurs allostériques positifs du récepteur muscarinique m1
MA44721B1 (fr) Inhibiteurs de mcl1 macrocycliques pour le traitement du cancer
TN2009000450A1 (fr) Derives de pyridine
MA32070B1 (fr) Dérivés hétérocycliques réunis par fusion et procédés d'utilisation associés
MA45153B1 (fr) Dérivés de carbonucléosides substitués utiles en tant qu'agents anticancéreux
TNSN08445A1 (fr) Derives de triazolopyrazine utiles comme agent anticancereux
MA29926B1 (fr) Derives de pyrazine
MA37400B1 (fr) Composés hétérocyclyle en tant qu'inhibiteurs de mek
MA34819B1 (fr) Dérivés bicyclo[3.2.1]octylamide et leurs utilisations
MA51204B1 (fr) Formes pharmaceutiques comprenant un inhibiteur de la kallicréine plasmatique
MA45782B1 (fr) Modulateurs du récepteur de cxcr7 pipéridine
MA38138A1 (fr) Dérivés inédits de quinolone
TNSN07022A1 (fr) Derives de pyridine
MA38175A1 (fr) Lactames fusionnés à un aryle et hétéroaryle
MA33364B1 (fr) Dérivés aminobutyriques substitués en tant qu'inhibiteurs de néprilysine
MA29791B1 (fr) Composes therapeutiques.
MA49127B1 (fr) Dérivés d'indole n-substitués
MA30916B1 (fr) Nouveaux derives de benzamide en tant qu'antagonistes de bradykinine
MA31170B1 (fr) Dérivés de 2-amino-5,7-dihydro-6h-pyrrolo[3,4-d]pyrimidine servant d'inhibiteurs de la hsp-90 pour le traitement du cancer
MA50013B1 (fr) Analogues de benzoazépine utilisés en tant qu'agents inhibiteurs de la tyrosine kinase de bruton
MA46229B1 (fr) Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2
MA41633B1 (fr) Composés amide en tant qu'agonistes du récepteur 5-ht4